Excelsior Biopharma (Taiwan) Insiders
| 6496 Stock | TWD 29.10 0.40 1.36% |
Excelsior Biopharma employs about 23 people. The company is managed by 5 executives with a total tenure of roughly 54 years, averaging almost 10.0 years of service per executive, having 4.6 employees per reported executive. Recap of Excelsior Biopharma's management performance can provide insight into the venture performance.
| HuiChen Liu Insider Representative Mang |
| Joseph Chen Insider Chairman, Founder |
Excelsior |
Excelsior Biopharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.0116) % which means that it has lost $0.0116 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0288) %, meaning that it generated substantial loss on money invested by shareholders. Excelsior Biopharma's management efficiency ratios could be used to measure how well Excelsior Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Excelsior Biopharma Workforce Comparison
Excelsior Biopharma is number one stock in number of employees category among its peers. The total workforce of Drug Manufacturers-Specialty & Generic industry is presently estimated at about 134. Excelsior Biopharma retains roughly 23.0 in number of employees claiming about 17% of equities under Drug Manufacturers-Specialty & Generic industry.
The company has Profit Margin (PM) of (0.04) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.04) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.04. Excelsior Biopharma Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Excelsior Biopharma Price Series Summation is a cross summation of Excelsior Biopharma price series and its benchmark/peer.
Excelsior Biopharma Notable Stakeholders
An Excelsior Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Excelsior Biopharma often face trade-offs trying to please all of them. Excelsior Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Excelsior Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| HuiChen Liu | Representative Mang | Profile | |
| Joseph Chen | Chairman, Founder | Profile | |
| MingTse Chen | Financial Accountant | Profile | |
| PoTang Cheng | Sales Director | Profile | |
| Chialing Chen | New Director | Profile |
About Excelsior Biopharma Management Performance
The success or failure of an entity such as Excelsior Biopharma often depends on how effective the management is. Excelsior Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Excelsior management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Excelsior management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please note, the imprecision that can be found in Excelsior Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Excelsior Biopharma. Check Excelsior Biopharma's Beneish M Score to see the likelihood of Excelsior Biopharma's management manipulating its earnings.
Excelsior Biopharma Workforce Analysis
Traditionally, organizations such as Excelsior Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Excelsior Biopharma within its industry.Excelsior Biopharma Manpower Efficiency
Return on Excelsior Biopharma Manpower
| Revenue Per Employee | 58.2M | |
| Revenue Per Executive | 267.7M | |
| Net Loss Per Employee | 680.4K | |
| Net Loss Per Executive | 3.1M |
Additional Tools for Excelsior Stock Analysis
When running Excelsior Biopharma's price analysis, check to measure Excelsior Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Excelsior Biopharma is operating at the current time. Most of Excelsior Biopharma's value examination focuses on studying past and present price action to predict the probability of Excelsior Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Excelsior Biopharma's price. Additionally, you may evaluate how the addition of Excelsior Biopharma to your portfolios can decrease your overall portfolio volatility.